ΔNp63, also known as p40, regulates stemness of normal mammary gland epithelium and provides stem cell characteristics in basal and HER2-driven murine breast cancer models. Whilst ΔNp63/p40 is a characteristic feature of normal basal cells and basal-type triple-negative breast cancer, some receptor-positive breast cancers express ΔNp63/p40 and its overexpression imparts cancer stem cell-like properties in ER+ cell lines. However, the incidence of ER+ and HER2+ tumours that express ΔNp63/p40 is unclear and the phenotype of ΔNp63/p40+ cells in these tumours remains uncertain. Using immunohistochemistry with p63 isoform-specific antibodies, we identified a ΔNp63/p40+ tumour cell subpopulation in 100 of 173 (58%) non-triple negative breast cancers and the presence of this population associated with improved survival in patients with ER- /HER2+ tumours (p = 0.006). Furthermore, 41% of ER+ /PR+ and/or HER2+ locally metastatic breast cancers expressed ΔNp63/p40, and these cells commonly accounted for <1% of the metastatic tumour cell population that localised to the tumour/stroma interface, exhibited an undifferentiated phenotype and were CD44+ /ALDH- . In vitro studies revealed that MCF7 and T47D (ER+ ) and BT-474 (HER2+ ) breast cancer cell lines similarly contained a small subpopulation of ΔNp63/p40+ cells that increased in mammospheres. In vivo, MCF7 xenografts contained ΔNp63/p40+ cells with a similar phenotype to primary ER+ cancers. Consistent with tumour samples, these cells also showed a distinct location at the tumour/stroma interface, suggesting a role for paracrine factors in the induction or maintenance of ΔNp63/p40. Thus, ΔNp63/p40 is commonly present in a small population of tumour cells with a distinct phenotype and location in ER+ and/or HER2+ human breast cancers.

Advanced Data Analysis Centre University of Nottingham Nottingham UK

Department of Pathology Ninewells Hospital and Medical School Dundee UK

Division of Surgical Oncology Dan L Duncan Comprehensive Cancer Center Baylor College of Medicine Houston TX USA

Dundee Cancer Centre University of Dundee Ninewells Hospital and Medical School Dundee UK

NCRC University of Michigan Ann Arbor MI USA

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czech Republic

Zobrazit více v PubMed

Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 2010; 5: 349–371. PubMed

Nekulova M, Holcakova J, Coates P, PubMed PMC

Melino G, Memmi EM, Pelicci PG, PubMed

Barbareschi M, Pecciarini L, Cangi MG, PubMed

Ribeiro‐Silva A, Zambelli Ramalho LN, Britto Garcia S, PubMed

Wang X, Mori I, Tang W, PubMed

Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004; 28: 1506–1512. PubMed

Ali HR, Dawson S‐J, Blows FM, PubMed PMC

Kim J, Villadsen R, Sørlie T, PubMed PMC

Liu S, Cong Y, Wang D, PubMed PMC

Liu Y, Nenutil R, Appleyard MV, PubMed PMC

Brooks MD, Burness ML, Wicha MS. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell 2015; 17: 260–271. PubMed PMC

Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 2015; 16: 225–238. PubMed PMC

Balboni AL, Hutchinson JA, DeCastro AJ, PubMed PMC

Chakrabarti R, Wei Y, Hwang J, PubMed PMC

Memmi EM, Sanarico AG, Giacobbe A, PubMed PMC

Du Z, Li J, Wang L, PubMed PMC

Amin R, Morita‐Fujimura Y, Tawarayama H, PubMed PMC

Matos I, Dufloth R, Alvarenga M, PubMed

Kumar S, Wilkes DW, Samuel N, PubMed PMC

Orzol P, Nekulova M, Holcakova J, PubMed

Nekulova M, Holcakova J, Gu X, PubMed PMC

Holcakova J, Nekulova M, Orzol P, PubMed

Coates PJ, Nenutil R, Holcakova J, PubMed

Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in ductal carcinoma PubMed

Lee AHS. Use of immunohistochemistry in the diagnosis of problematic breast lesions. J Clin Pathol 2013; 66: 471–477. PubMed

Baker L, Quinlan PR, Patten N, PubMed PMC

Bouchalova P, Nenutil R, Muller P, PubMed

Appleyard MVCL, Murray KE, Coates PJ, PubMed PMC

Nylander K, Vojtesek B, Nenutil R, PubMed

Nekulova M, Holcakova J, Nenutil R, PubMed

Detre S, Saclani Jotti G, Dowsett MA. ‘QuickScore’ method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48: 876–878. PubMed PMC

Buckley NE, Conlon SJ, Jirstrom K, PubMed

Hanker L, Karn T, Ruckhaeberle E, PubMed

de Biase D, Morandi L, Degli Esposti R, PubMed

Stingl J. Detection and analysis of mammary gland stem cells. J Pathol 2009; 217: 229–241. PubMed

Al‐Hajj M, Wicha MS, Benito‐Hernandez A, PubMed PMC

Abraham BK, Fritz P, McClellan M, PubMed

Dontu G, Abdallah WM, Foley JM, PubMed PMC

Yallowitz AR, Alexandrova EM, Talos F, PubMed PMC

Hu L, Liang S, Chen H, PubMed PMC

Fichter CD, Przypadlo CM, Buck A, PubMed PMC

McCart Reed AE, Kalita‐De Croft P, Kutasovic JE, PubMed

Gerdes MJ, Gökmen‐Polar Y, Sui Y, PubMed PMC

Heterogeneous protein dynamics links to mitochondrial activity, glucose transporter, and ALDH cancer stem cell properties

Stat3 Tyrosine 705 and Serine 727 Phosphorylation Associate With Clinicopathological Characteristics and Distinct Tumor Cell Phenotypes in Triple-Negative Breast Cancer

DNA Demethylation Switches Oncogenic ΔNp63 to Tumor Suppressive TAp63 in Squamous Cell Carcinoma

Identifying pathways regulating the oncogenic p53 family member ΔNp63 provides therapeutic avenues for squamous cell carcinoma

TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis